Journey Medical Reports Lower-Than-Expected Non-GAAP EPS and Revenue

Trending News 🌥️

Journey Medical ($NASDAQ:DERM) Corporation recently reported their Non-GAAP earnings per share (EPS) and revenue, and both numbers fell short of the predicted estimates. The company reported a Non-GAAP EPS of -$0.30 and revenue of $12.2M, missing the estimate by $3.98M. Journey Medical Corporation is a publicly traded healthcare company that specializes in the distribution of medical supplies and services. The company provides a wide range of services to hospitals, physicians, and other healthcare providers. They are dedicated to providing quality products and services at competitive prices, ensuring that their customers experience the highest levels of satisfaction.

Despite the lower-than-expected Non-GAAP EPS and revenue, Journey Medical remains confident in their ability to deliver high-quality products and services. The company is continuously looking for ways to improve their operations, and they will continue to focus on customer satisfaction and innovation. They remain committed to delivering sustainable value for their shareholders in the long-term.

Earnings

JOURNEY MEDICAL released their quarterly earnings report for Fiscal Year 2022 Q4, which ended December 31, 2022. The report showed that JOURNEY MEDICAL had a total revenue of 15.97 million USD, resulting in a net income loss of 10.64 million USD. This represented an 8.8% decrease in total revenue compared to the previous year.

However, JOURNEY MEDICAL’s total revenue had increased from 13.72 million USD to 15.97 million USD over the last three years. These results were lower than expected and have caused shares to drop in value.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Journey Medical. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Journey Medical. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Journey Medical. More…

Key Ratios Snapshot

Some of the financial key ratios for Journey Medical are shown below. More…

Share Price

The stock opened that day at $1.4 and closed at $1.4, up by 2.9% from the previous closing price. This difference between expectations and actual results has caused investors to question the future prospects for the company. Despite the lower-than-expected performance, investors still seem positive on JOURNEY MEDICAL as evidenced by the increase in share price on Monday. It remains to be seen whether JOURNEY MEDICAL can improve its performance over the next quarter and meet analysts’ expectations in order to sustain investor confidence. Live Quote…

Analysis

As a financial analyst with GoodWhale, I recently evaluated the financials of JOURNEY MEDICAL. After using the Star Chart to classify the company, I concluded that JOURNEY MEDICAL is a ‘gorilla’ type of company. This indicates that the company has a strong competitive advantage and has achieved stable and high revenue or earning growth. Given JOURNEY MEDICAL’s successful financial performance, I believe that investors looking for a long-term, high return investment may find this company attractive. Moreover, JOURNEY MEDICAL has an intermediate health score of 6/10. This suggests that while there may be some issues with its cashflows and debt structure, the company is in a strong enough financial position to sustain operations in times of crisis. When assessing JOURNEY MEDICAL’s overall financial health, I found that the company was strong in terms of growth, medium in terms of asset, profitability and weak in terms of dividend. This reflects the company’s focus on achieving sustainable growth rather than solely focusing on short-term gains. As such, investors seeking a long-term, high return investment should consider JOURNEY MEDICAL as a potential option. More…

Peers

Journey Medical Corp is one of the leading medical research companies in the industry, competing with several other prominent firms such as Nutri Pharmaceuticals Research Inc, Gaia Grow Corp, and CBD Life Sciences Inc. With a commitment to innovative research and development, Journey Medical Corp is dedicated to providing cutting-edge technology and treatments that make a real difference in people’s lives.

– Nutri Pharmaceuticals Research Inc ($OTCPK:NRPR)

Gaia Grow Corp is a leading provider of sustainable farming and agricultural technology solutions. The company is committed to improving the lives of farmers and helping them achieve higher yields and better quality produce. The company’s market cap of 180.18k as of 2023 reflects its successful implementation of innovative sustainable farming practices that are profitable and ecologically beneficial. Gaia Grow Corp has a strong Return on Equity (ROE) of 570.7%, indicating that their strategies and investments are generating high returns. With its strong financial performance, the company is well-positioned to continue its growth trajectory and further expand its presence in the global market.

– Gaia Grow Corp ($BER:GG00)

CBD Life Sciences Inc is a publicly traded company that specializes in the production, distribution, and sale of hemp-based products. As of 2023, the company’s market cap stands at 35.85k. This market cap provides investors with an indication of the company’s value. Additionally, the company’s Return on Equity (ROE) is -28.26%. ROE measures how well a company has been able to generate profits from its existing stockholder equity. Although the current ROE is negative, it indicates that the company has been able to put its funds in place to generate profits.

Summary

Journey Medical Corporation reported a Non-GAAP earnings per share (EPS) of -$0.30 and revenue of $12.2M in its recent earnings report, which was a miss of $3.98M compared to analyst expectations. This was an overall decline compared to the same period last year. The poor performance is likely due to rising costs in the healthcare sector coupled with increasing competition and decreasing consumer demand. Investors should consider the challenges faced by the company and its competitive landscape when making decisions regarding investments in Journey Medical Corporation.